Changes in Eosinophil as potential marker for immune-related changes associated with PRRT in NET

#3291

Introduction: Eosinophil (E) accumulation under immune checkpoint inhibitors (ICI) in cancer patients’ blood has been shown to have predictive value. Peptide Receptor Radionuclide Therapy (PRRT) can remodel tumor environment for ICI in G1 / G2 neuroendocrine tumor patients.

Aim(s): To evaluate the ΔE as well as Neutrophil (N) / E ratio pre and post PRRT and their correlation with PET/CT-based response.

Materials and methods: Pre and post PRRT (median 4 cycles; mean 6.89±0.93 GBq / Lu-177-DOTAiTATE cycle) lab data of 61 G1/G2 NET patients (F:M 26:35; 68 ±11 y) were analysed. Response was assessed using Ga-68 Somatostatin Receptor (SSTR) PET/ceCT. The values of (E, N, N/E) at baseline and after 1st/2nd PRRT were compared; p<0.05 was considered to be significant.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Prasad V

Authors: Grunert M, Quast D, Ettrich T, Glatting G, Beer A,

Keywords: eosinophil, PRRT, NET, tumor microenvironment,